Mark Avagliano

2020

In 2020, Mark Avagliano earned a total compensation of $1.4M as Chief Business Officer at G1 Therapeutics, a 74% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$151,200
Option Awards$837,165
Salary$431,417
Other$18,445
Total$1,438,227

Avagliano received $837.2K in option awards, accounting for 58% of the total pay in 2020.

Avagliano also received $151.2K in non-equity incentive plan, $431.4K in salary and $18.4K in other compensation.

Rankings

In 2020, Mark Avagliano's compensation ranked 7,018th out of 13,090 executives tracked by ExecPay. In other words, Avagliano earned more than 46.4% of executives.

ClassificationRankingPercentile
All
7,018
out of 13,090
46th
Division
Manufacturing
2,929
out of 5,618
48th
Major group
Chemicals And Allied Products
1,182
out of 2,251
48th
Industry group
Drugs
1,016
out of 1,951
48th
Industry
Pharmaceutical Preparations
756
out of 1,456
48th
Source: SEC filing on April 28, 2021.

Avagliano's colleagues

We found five more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2020.

2020

Mark Velleca

G1 Therapeutics

Chief Executive Officer

2020

Soma Gupta

G1 Therapeutics

Chief Commercial Officer

2020

Jennifer Moses

G1 Therapeutics

Chief Financial Officer

2020

Rajesh Malik

G1 Therapeutics

Chief Medical Officer

2020

John Bailey

G1 Therapeutics

Chief Executive Officer

News

In-depth

You may also like